Techsheet: Dr.Reddy's Lenvatinib API offerings
Lenvima is an oral tyrosine kinase inhibitor approved in multiple indications, including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
We offer two polymorphic forms:
1) Lenvatinib Mesylate MIBK solvate
2) Lenvatinib Mesylate Form-C.
A MIBK solvate is a novel form that offers in several markets an early launch advantage over the polymorph patent.
The US DMF has been filed for both forms:
* Lenvatinib Mesylate MIBK solvate in June 2018.
* Lenvatinib Mesylate Form-C anhydrous in June 2021.
We are well-positioned to meet the global demand for Lenvatinib API, with the ability to scale-up to meet commercial requirements whenever needed. Want to know more about our API offerings, please fill in the contact details below.
Explore other Whitepapers:Know More
- Email us: email@example.com
- +91 40 49002222
Please fill the Contact form below in order to view the white paper